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Superantigens are proteins comprising a group of molecules produced by various microorganisms. They are involved in
pathogenesis ofseveralhumandiseases.The aim of the study was the comparisonofsusceptibility to antibiotics andantimicrobial
peptides (AMPs) of Staphylococcus aureus (SA) strains producing staphylococcal enterotoxins SEA, SEB, SEC, SED, and TSST-1
and nonproducing ones. In the group of the total 28 of the patients with erythrodermia the presence of SA was conﬁrmed in 24
cases. The total of 14 strains of SA excreted enterotoxins SEA, SEC, SED, and TSST-1. We did not observe that strains producing
mentioned superantigens were less susceptible to AMPs (aurein 1.2, citropin 1.1, lipopeptide, protegrin 1, tachyplesin 3, temporin
A, and uperin 3.6). The opposite situation was observed in conventional antibiotics. SA strains excreting tested superantigens
had higher MICs and MBCs than nonproducing ones. The interesting ﬁnding considering the high eﬃcacy of AMPs, against all
examined strains of SA, makes them attractive candidates for therapeutic implication.
1.Introduction
Superantigens are proteins comprising a group of molecu-
les produced by various microorganisms, such as bacte-
ria (staphylococci, streptococci, and mycoplasma), fungi
(yeasts), and viruses. They are involved in the pathogenesis
of several human diseases (atopic eczema, toxic shock syn-
drome, psoriasis, and Kawasaki disease) [1]. Superantigens
are characterized by their capacity to stimulate a large num-
ber of T-cells. In contrast to conventional antigens, superan-
tigens bypass avoidintracellular processing and bind directly
tothemajorhistocompatibilitycomplex(MHC)classIImol-
ecule, on the surface of the antigen processing cell, outside
the antigen-binding groove [2]. T-cells belonging to both
the CD4 and CD8 subtype are activated. T-cell activation in
the presence of superantigens may lead to the activation of
several percent of the total T-cell population, and thereby
activate by a factor of more than 10–100 the number of T-
cells activated in the presence of conventional antigens [3].
Some 80 to 100 percent of atopic dermatitis (AD) pa-
tients have skin colonization with Staphylococcusaureus (SA)
[4].Ithasbeenfoundonboththehealthyandlesionalskinof
those patients. SA superantigens are a well-known AD-ex-
acerbatingfactor. Thepathogensconcentration(cfu/cm2)on
the skin of atopic dermatitis patients is signiﬁcantly higher
than on that of healthy population [5]. Suppressed levels2 Chemotherapy Research and Practice
of ceramides, free lipoid acids, superﬁcial polar lipids, skin
natural antimicrobial peptides(LL-37, β-defensin), as well as
the pH shifted to alkaline region (7-8), ﬁbronectin receptors
exposure of adhesin-binding cell wall of SA, and destruction
of the skin barrier by substances excreted by these germs are
responsible for SA skin colonization in AD [6–8].
TheaggravatingroleofSAsuperantigensiswellknownin
ADbuthas not beenwell documentedin psoriasis. There are
single reports concerning correlation between the severity of
AD and psoriasis and enterotoxin production of isolated SA
strains [9].
There are single reports conﬁrming the relationship be-
tween erythrodermic cutaneous T-cell lymphoma (CTCL)
and superantigens producing SA colonization [10]. It has
been demonstrated that antibiotic therapy in CTCL can
suppress inﬂammation and the size of neoplastic tumours
in those cases. The relationship between staphylococcal skin
infectionsanderythrodermicCTCLneedsexploration.Itcan
behypothesized that likeotherT-cell-mediated skin diseases,
CTCL occurs in the setting of a genetically determined host
(HLA determinants), a trigger (antigens or superantigens),
and an immune response with cytokine and chemokine
production. In CTCL, T-cells are attracted into the epider-
mis, and they may be unable to limit their proliferation
(absent apoptosis). SA superantigen presented either by
Langerhans cells or by class-II-bearing keratinocytes results
i nc y t o k i n e st h a ts t i m u l a t eT - c e l l s .I ti sr e a s o n a b l et h a tp e r -
sistentcolonizationwithtoxigenicbacteriawouldexpandthe
population of epidermotropic T-cells and elicit production
of T-cell-activating cytokine/chemokines [11, 12].
Bering in mind that the enhanced resistance of bacteria
to conventional antibiotics is a serious problem in present-
day healthcare, the developmentof novel antimicrobial ther-
apies, such as those based on various antimicrobial peptides,
seems to be reasonable.
Humans express a blend of antimicrobial peptides
(AMPs), which are found at biological boundaries prone to
infection. One of the most important innate defense mech-
anisms of the human skin is the production of AMPs.
They are produced mainly by keratinocytes in the stratum
corneum, neutrophils, or by sweat glands and are either
expressedconstitutivelylikeRNase7,psoriasin, ordermcidin
or after an inﬂammatory stimulus like β-defensin-2 (HBD-
2) and -3 (HBD-3) or the cathelicidin LL-37 [13]. AMPs
kill bacteria by permeating their membranes, and thus,
the lack of a speciﬁc molecular microbial target minimizes
resistance development [14]. Actually, several peptides and
peptide-based compounds are passing clinical trials [15].
Expression levels of these natural antibiotics correlate well
with susceptibility to skin infections [16].
Herein, we investigated SA colonization in patients with
erythrodermia (a skin inﬂammation of more than 90% of
bodysurface)thatdevelopedinthecourseofpsoriasis,atopic
dermatitis, cutaneousT-cell lymphoma, orSezary Syndrome
(SS) [17, 18]. The isolated bacterial strains were analyzed
for the superantigen excretion and susceptibility to conven-
tional antibiotics and selected AMPs (aurein 1.2, citropin
1.1, lipopeptide Pal-KK-NH2,p r o t e g r i n1 ,t a c h y p l e s i n3 ,
temporin A, and uperin 3.6).
2.Materialsand Methods
2.1. Antimicrobial Peptides. Peptides (aurein 1.2, citropin
1.1, lipopeptide Pal-KK-NH2,p r o t e g r i n1 ,t a c h y p l e s i n3 ,
temporin A, and uperin 3.6) included in the study were
synthesized manually in a microwave reactor by the solid-
phase method using the 9-ﬂuorenylmethoxycarbonyl chem-
istry (Fmoc) [19, 20]. The completeness of each coupling
reaction was monitored by the chloranil test. The peptides
were cleaved from the solid support by triﬂuoroacetic acid
(TFA) in the presence of water (2.5%) and triisopropylsilane
(2.5%) as scavengers. The cleaved peptides were precipitated
with diethyl ether, and cysteine-containing ones peptides
were oxidized by 0.1M iodine in methanol. The peptides
were puriﬁed by high-performance liquid chromatography
(HPLC). The resulting fractions of purity greater than 95%–
98% were tested by HPLC and thin layer chromatography
(TLC) for lipopeptide. The peptides were analyzed also by
matrix-assisted laser desorption ionization time of ﬂight
mass spectrometry (MALDI-TOF MS).
2.2. Bacterial Isolates and Antibiotics Disk Susceptibility Test.
Twenty-eight patients with erythrodermia, hospitalized at
the Department of Dermatology, Venereology, and Aller-
gology from January 2007 to October 2008, were enrolled
in the study. From each patient, skin swabs were taken.
All samples were cultured on the Columbia agar plates
(BectonDickinson, Germany) using standard microbiological
procedures. SA was identiﬁed on the basis of colony mor-
phology, production of catalase, and positive slide coagu-
lation test (Staphaurex and Biomerieux). The susceptibility
to antibiotics was determined by disk diﬀusion method as
recommended by CLSI (Clinical Laboratory Standards Insti-
tute) guidelines. The following antimicrobials were tested:
penicillin,oxacillin,erythromycin,doxycycline,clindamycin,
rifampicin, chloramphenicol, linezolid, daptomycin, tigecy-
cline, and ciproﬂoxacin (Oxoid, UK). The susceptibility tests
were performed on the Mueller-Hinton II (Becton Dick-
inson). The results obtained by disk diﬀusion were compared
to those of the broth microdilution in the case of linezolid,
daptomycin, tigecycline, rifampicin, chloramphenicol, ery-
thromycin, and clindamycin.
2.3. Enterotoxin Detection. A staphylococcal enterotoxin test
kit (SET-RPLA KIT TOXIN DETECTION KIT, Oxoid)w a s
used for the detection of staphylococcal enterotoxins A, B,
C ,a n dDi nc u l t u r eb yr e v e r s e dp assive latex agglutination.
Clinical strains of SA were incubated in Tryptone Soy
Broth (Becton Dickinson)a n di n c u b a t e da t3 7 ◦C for 18–24
hours, with shaking on a water bath. After growth, they
were centrifuged at 900g for 20 minutes at 4◦C, and the
supernatants were used as the test sample. Latex sensitised
with antienterotoxin A, B, C, or D was added to ﬁlter-
sterilized supernatants on V-well microtiter plates (Sigma-
Aldrich, Germany). A visible agglutination on the bottom of
the well was considered as a positive result.
2.4. TSST Detection. A staphylococcal toxic shock syndrome
toxin kit (TST-RPLA TOXIN DETECTION KIT, Oxoid)w a sChemotherapy Research and Practice 3
used for the detection of a staphylococcal toxic shock syn-
drome toxin in culture by reversed passive latex agglutina-
tion. Clinical strains of S. aureus were incubated in a brain-
heart infusion broth (Becton Dickinson)a n di n c u b a t e da t
37◦C for 18–24 hours, with shaking on a water bath. After
growth, they were centrifuged at 900g for 20 minutes at 4◦C,
and the supernatants were used as the test sample. Latex
sensitized with antitoxin was added to ﬁlter-sterilized super-
natants on V-well microtiter plates(Sigma-Aldrich). Avisible
agglutination on the bottom of the well was considered as a
positive result.
2.5.Microorganisms andAntimicrobialAssay. Atotalnumber
of 24 SA strains were obtained from patients with erythro-
dermiaand 3 referenceSAones fromthe American Type Cul-
ture Collection: 6538P ATCC, 9144 ATCC, and 25923 ATCC
(Institute of Experimental Therapy, Wroclaw, Poland). MIC
was determined using a microbroth dilution method with
the Mueller Hinton Broth II (MHB II) (Becton Dickinson)
and initial inoculums of 5×105 CFU/mL. Polypropylene 96-
well plates (Sigma-Aldrich) were incubated for 18h at 37◦C.
MIC was taken as the lowest drug concentration at which
a noticeable growth was inhibited. MBC was taken as the
lowest concentration of each drug that resulted in more than
99.9% reduction of the initial inoculums. The experiments
were performed in triplicate.
3.Results
3.1.StaphylococcusAureusIsolation. Inagroupof28patients
with erythrodermia (11 in the course of psoriasis, 9 with
atopic dermatitis, 6 with CTCL, and 2—Sezary syndrome)
the presence of SA was conﬁrmed in 24 cases. Negative
cultures for SA were noticed in three patients with psoriasis.
3.2.Superantigens Detection. Atotalnumber of14 SAstrains
excretedenterotoxinsSEA(8strains), SEC(3strains), and/or
SED (5 strains) and only one TSST-1 in the group of 24.
Intermediate results (+/−) were considered as negative. In
the groupof 9 patientswith AD,the superantigen-producing
strains were detected in 6 patients, in the group of 6 patients
with CTCL—in 3 cases and in 8 patients with psoriasis—in
3 cases. SA strains isolated from two patients with SS did not
produce the above-mentioned superantigens.
3.3. Antibiotics and Antimicrobial Peptides Susceptibility. The
susceptibility to antibiotics determined by the disk diﬀusion
method and broth microdilution gave identical results (data
not shown). The antibiotics used in the study, rifampicin,
tigecyline,vancomycin, daptomycin, ciproﬂoxacin,chloram-
phenicol, clindamycin, and erythromycin, exhibited diverse
activities against clinical isolates of SA. The rifampicin,
tigecycline, vancomycin, and daptomycin MICs values,
which were the lowest among the tested antibiotics, varied
between 1 and 4mg/L. The other ones were higher than the
tested antimicrobial peptides: tachyplesin 3, lipopeptide,and
protegrin 1 were extremely eﬀective against all the tested
bacterial strains (MIC values between 1 and 8mg/L); see
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Figure 1: The relationship between superantigen production and
susceptibility to conventional antibiotics.
Table 1. The reference strains were more susceptible to both
conventionalantibioticsand AMPsthanthe clinicalones;see
Table 2.
3.4. Correlation Study. We did not notice that strains pro-
ducing tested superantigens (SEA, SEC, SED, and TSST-1)
were less susceptible to AMPs than nonproducing ones. The
opposite situation was observed in conventional antibiotics.
SA strains excreting those superantigens had higher MICs
and MBCs Figures 1 and 2.
4.Discussion
Bacterial superantigens, which stimulate clonal expansion
of T-cells by mechanisms involving speciﬁc HLA molecules,
have also been hypothesized to cause inﬂammatory skin dis-
eases [10].The mechanisms bywhich these toxins act remain
still unknown. This is the ﬁrst report of the occurrence of
staphylococcus superantigens in erythrodermic skin diseases
(AD, psoriasis, CTCL, and SS).
There are many studies that explain the eﬀect of SA on
AD [21]. Most SA strains isolated from AD patients can
producesuperantigenictoxinssuchasstaphylococcal entero-
toxin SEA, SEB, SEC, SED, and the toxic shock syndrome
toxin-1 (TSST-1) that correspond well with our ﬁndings
(66.7% of strains excreted tested superantigens). Coloniza-
tionand infectionwithStaphylococcusand Streptococcushave
been reported to exacerbate psoriasis [22, 23]. The presence
ofSAinpsoriaticerythrodermiawasconﬁrmedin8outof11
patients,whiletheabilitytoproduceexaminedsuperantigens
was detected in 3 strains. CTCL patients resemble those with
acquired immunodeﬁciency syndrome who cannot clear
the skin oﬀ staphylococcus and have protracted pruritus
and erythrodermic psoriasis [10]. The association between
staphylococcal colonization and the erythrodermic form of
CTCL deserves further attention and study. The strains
excreting speciﬁed superantigens colonized 50% of patients
with CTCL in our study.4 Chemotherapy Research and Practice
Table 1: The activity of antimicrobial peptides and conventional antibiotics against S. aureus clinical isolates.
Strain (no. of isolates) and agent MIC (mg/liter) MBC (mg/liter)
Range 50% 90% Range 50% 90%
Superantigen negative S. aureus (10)
Tachyplesin 3 1–4 2 4 2–4 2 4
Lipopeptide 1–8 2 4 2–8 4 8
Protegrin 1 1–4 2 4 2–8 4 8
Temporin A 8–32 8 16 16–64 16 32
Citropin 1.1 8–32 16 32 16–64 16 64
Aurein 1.2 32–128 64 128 64–128 64 128
Uperin 3.6 128–256 128 128 128-128 128 128
Rifampicin 0.25–1 0.25 1 1-2 0.25 1
Tigecycline 0.5–1 0.5 0.5 1-2 1 1
Linezolid 0.5–2 1 1 NT NT NT
Vancomycin 0.5–1 1 1 1–4 1 2
Daptomycin 1–4 1 2 1–4 2 2
Ciproﬂoxacin 0.25–0.5 0.25 0.5 1–8 1 4
Chloramphenicol 2–32 4 32 8–32 8 32
Erythromycin 0.25–64 0.5 0.5 1–4 1 2
Clindamycin 16–64 32 32 64–128 32 64
Superantigen positive S. aureus (14)
Tachyplesin 3 1–4 2 4 2–4 2 4
Lipopeptide 1–8 2 4 2–8 4 8
Protegrin 1 1–4 2 4 2–8 4 8
Temporin A 8–32 8 16 16–64 32 64
Citropin 1.1 8–32 16 32 16–64 16 64
Aurein 1.2 32–128 64 128 64–128 64 128
Uperin 3.6 128–256 128 128 128-128 128 128
Rifampicin 0.25–1 0.25 1 0.5–2 1 2
Tigecycline 0.5–1 0.5 0.5 1-2 1 1
Linezolid 0.5–2 1 2 NT NT NT
Vancomycin 0.5–2 1 2 1–4 2 4
Daptomycin 1–4 1 2 1–4 2 4
Ciproﬂoxacin 0.25–128 2 32 2–128 4 64
Chloramphenicol 4–128 8 64 8–128 16 128
Erythromycin 0.25–512 1 256 4–512 8 128
Clindamycin 8–512 64 512 16–512 64 128
We found that 24 out of 28 erythrodermic patients had
a staphylococcal culture positive from the skin, and tested
superantigens were detected in SA strains isolated from 14
patients.Thepurposeofourstudy wastoinvestigatewhether
or not the strains producing SEA, SEC, SED, and TSST-1 are
more resistant to conventional antibiotics and AMPs. Con-
sidering susceptibility to antimicrobial peptides, we did not
notice any signiﬁcant diﬀerences between strains producing
testedsuperantigensandnonproducingstrains. Theopposite
situationwas noticedinsusceptibilitytoconventionalantibi-
otics. The SA strains producing speciﬁed superantigens had
higher MICs and MBCs as compared to the nonproducing
ones. Especially alarming is the higher resistance of those
strains to macrolides and lincosamides which could not only
kill bacteria and diminish the rate of colonization but also
inhibit their superantigen and toxin production [24, 25].
One study showed that β-lactams which target cell wall
development in bacteria and are the basis for the treatment
ofskinand soft-tissue infections couldevenincrease the pro-
duction of toxins [25]. SA strains which can produce super-
antigens and toxins and additionally acquire the mechanism
(i.e., resistance) protecting their production are the most
diﬃcult to control. Adachi et al. speculated that inhibitors
of protein synthesis may have an antimicrobial eﬀect and
also inhibitory eﬀect on superantigen production from SA
[24]. In fact, the inhibition of superantigen production by
antibiotics may not be suﬃcient to justify clinical eﬃcacy.
Over 50% incidence of production of tested superanti-
gens in strains from AD patients is in accordance with pre-
vious studies [26].Chemotherapy Research and Practice 5
Table 2: The activity of antimicrobial peptides and conventional
antibiotics against S. aureus referential strains.
MIC (mg/liter)
ATCC 6538P ATCC 9144 ATCC 25923
Tachyplesin 3 222
Lipopeptide 224
Protegrin 1 424
Temporin A 81 6 1 6
Citropin 1.1 83 2 3 2
Aurein 1.2 64 64 64
Uperin 3.6 64 64 128
Rifampicin 0.25 0.25 0.25
Tigecycline 0.25 0.25 0.25
Linezolid 0.5 1 0.5
Vancomycin 121
Daptomycin 222
Ciproﬂoxacin 121
Chloramphenicol 444
Erythromycin 111
Clindamycin 422
Several studies on the eﬀect of antimicrobial treatment
onthecolonizationwith SAandtheseverityofinﬂammation
gave conﬂicting results. In several open or double-blind
placebo-controlled trials, topical or systemic antibiotics were
able to reduce colonization density and led to a partial
improvement of skin lesions [27–29]. On the other hand,
treatment with oral antibiotics did not lead to a signiﬁcant
improvement of AD in two double-blind placebo-controlled
studies [30, 31]. No matter what kind of the treatment
has been adopted, recolonization occurred after 4–8 weeks
[32].
5.Conclusions
From a clinical point of view, our study has several implica-
tions.Consideringthaterythrodermicpatientsarefrequently
treated with various antibiotics, the question may be raised
whether excessive use of antibiotics and induction of resis-
tanceareassociated with cross-resistance toAMPs. Wefound
no evidence for the development of the AMPs resistance
in relation to antibiotic susceptibility, likely reﬂecting the
fact that the mode of action of the antibiotics investigated
herein is not shared with AMPs. An interesting ﬁnding of
the high eﬃcacy of AMPs, especially lipopeptides, against
all tested strains of SA makes them attractive candidates for
therapeutic application.
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Figure 2: The relationship between superantigen production and
susceptibility to antimicrobial peptides.
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